

# Kent Academic Repository

## Full text document (pdf)

### Citation for published version

Neto, Martin Mayora, Cantoni, Diego, Genova, Cecilia di, Scott, Simon D., Derveni, Mariliza, Wright, Edward and Temperton, Nigel J. (2022) Comparison of lentiviral and vesicular stomatitis virus core SARS-CoV-2 pseudotypes and generation of a stable cell line for use in antibody neutralisation assays. In: Access Microbiology. 4 (5).

### DOI

<https://doi.org/10.1099/acmi.ac2021.po0438>

### Link to record in KAR

<https://kar.kent.ac.uk/98156/>

### Document Version

Publisher pdf

#### Copyright & reuse

Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

#### Versions of research

The version in the Kent Academic Repository may differ from the final published version.

Users are advised to check <http://kar.kent.ac.uk> for the status of the paper. **Users should always cite the published version of record.**

#### Enquiries

For any further enquiries regarding the licence status of this document, please contact:

[researchsupport@kent.ac.uk](mailto:researchsupport@kent.ac.uk)

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at <http://kar.kent.ac.uk/contact.html>



# ACCESS MICROBIOLOGY

an open research platform

Volume 4, Issue 5

## Comparison of lentiviral and vesicular stomatitis virus core SARS-CoV-2 pseudotypes and generation of a stable cell line for use in antibody neutralisation assays

Martin Mayora Neto<sup>1</sup>, Diego Cantoni<sup>1</sup>, Cecilia di Genova<sup>1</sup>, Simon Scott<sup>1</sup>, Mariliza Derveni<sup>1</sup>, Edward Wright<sup>1</sup>, Nigel Temperton<sup>1</sup>

 View Affiliations

Published: 27 May 2022

Betacoronavirus SARS-CoV-2, the causative agent of COVID19, is a single stranded positive sense RNA virus. Since its emergence there has been great efforts to identify correlates of protection, which is crucial for vaccine evaluation studies. However, handling SARS-CoV-2 requires BSL-3 containment facilities slowing research efforts. Pseudotype viruses (PV) are a safe alternative to authentic virus that can be handled at low containment. PVs are chimeric viruses containing the core of a virus where its genome has been completely or partially replaced by a reporter gene, displaying a correctly folded SARS-CoV-2 spike on its surface. We developed lentiviral and vesicular stomatitis virus (VSV) core PVs alongside a stable A549 cell line expressing receptor ACE2 and protease TMPRSS2 responsible for S protein priming, for use in neutralization assays. Lentiviral PVs were generated by transfection with plasmids encoding the spike, HIV-1 gag-pol and a luciferase reporter. For VSV PVs, producer cells pre-transfected with the spike were infected with recombinant VSV expressing luciferase, before harvesting. The stable A549 cell line was generated by sequential infection of VSV-G PVs bearing lentiviral vectors encoding ACE2 and TMPRSS2 genes followed by antibiotic selection, before being tested in neutralization assays. We compared lentiviral and VSV PV platforms using monoclonal antibodies and convalescent sera with our stable A549 cells or HEK293T cells pre-transfected with plasmids encoding ACE2 and TMPRSS2. Antibody titres showed equivalence however VSV had the advantage of a shorter incubation therefore enabling a higher throughput. PVs offer a robust platform for future seroepidemiology and vaccine evaluation studies.

Published Online: 27/05/2022

© 2022 The Authors

This is an open-access article distributed under the terms of the Creative Commons Attribution License.

### Most read this month

---

### **Co-infection of SARS-CoV-2 with other respiratory pathogens in patients with liver disease**

Jasmine Samal, Reshu Agarwal, Anushka Soni, Amit Pandey, Shalini Thapar and Ekta Gupta

### **Case Report: *Vibrio fluvialis* isolated from a wound infection after a piercing trauma in the Baltic Sea**

Juliane Hecht, Maria Borowiak, Bernhard Fortmeier, Salah Dikou, Wolfgang Gierer, Ingo Klempien, Jonas Nekat, Stephan Schaefer and Eckhard Strauch

### ***Ralstonia mannitolilytica*: an emerging multidrug-resistant opportunistic pathogen in a tertiary care hospital setting**

Tasneem Siddiqui, Sangram Singh Patel, Richa Sinha, Ujjala Ghoshal and Chinmoy Sahu

### **Detection of *Enterococcus avium* in a case of urinary tract infection and haematuria**

Abdelrhman Abo-Zed, Shaymaa Hegazy and Tung Phan

### **Draft genome sequences of *Pseudomonas amygdali* pv. *loropetali* pathotype strain DSM 105780<sup>PT</sup>, isolated from Florida**

Apekshya Parajuli, Carrie L. Harmon, Gerald V. Minsavage, Debra D. Jones, Sujan Timilsina, Mathews L. Paret and Jeffrey B. Jones

## Most cited this month



### **Antibacterial activity of high-dose nitric oxide against pulmonary *Mycobacterium abscessus* disease**

Kristijan Bogdanovski, Trisha Chau, Chevalia J. Robinson, Sandra D. MacDonald, Ann M. Peterson, Christine M. Mashek, Windy A. Wallin, Mark Rimkus, Frederick Montgomery, Joas Lucas da Silva, Shashank Gupta, Abdi Ghaffari, Adrian M. Zelazny and Kenneth N. Olivier

### **Growth and metabolic characterization of four lactic acid bacteria species isolated from rice beer prepared in Assam, India**

Arup Jyoti Das, Manas Jyoti Das, Tatsuro Miyaji and Sankar Chandra Deka

### **Photodynamic antimicrobial chemotherapy coupled with the use of the photosensitizers methylene blue and temoporfin as a potential novel treatment for *Staphylococcus aureus* in burn infections**

Alistair Hampden-Martin, Jo Fothergill, Mohamed El Mohtadi, Lucy Chambers, Anthony J. Slate, Kathryn A. Whitehead and Kayvan Shokrollahi

### ***Ruminococcus gnavus* bacteraemia in a patient with multiple haematological malignancies**

Caroline Gren, Malene Roed Spiegelhauer, Emelie Curovic Rotbain, Boje Kvorning Ehmsen, Peter Kampmann and Leif Percival Andersen

### **Biosynthesis of silver nanoparticles using baker's yeast, *Saccharomyces cerevisiae* and its antibacterial activities**

Ifeyomi Olobayotan and Bukola Akin-Osanaiye

+ More

